November 20, 2014
Amniox® Medical Announces Study Confirming Superiority of Proprietary Cryopreservation Technology for Processing Umbilical Cord & Amniotic Membrane Tissue
ATLANTA – November 20, 2014 – Amniox Medical, Inc., a developer and marketer of regenerative therapies processed from umbilical cord and amniotic membrane, announces the publication of Comparison of Cryopreserved Amniotic Membrane and Umbilical Cord Tissue with Dehydrated Amniotic Membrane/Chorion Tissue in the October edition of the Journal of Wound Care. This study directly compares the CRYOTEK® preservation method with the PURION® (dehydration) processing method and demonstrates the following conclusions:
Cryopreservation retains the native architecture of the amniotic membrane (AM)/umbilical cord (UC) extracellular matrix. Dehydration dramatically compacts the tissue, suggesting alteration of critical components within.
Cryopreservation maintains the quantity and activity of key biological signaling proteins (specifically the Heavy Chain Hyaluronic Acid/Pentraxin 3 complex) present in fresh AM/UC. In contrast, dehydrated tissues almost completely lacked these crucial components. This effector molecule is responsible for promoting regenerative healing.
Amniox Medical is the only provider of a human tissue matrix composed of both umbilical cord and amniotic membrane. These tissues have innate regenerative properties that can be preserved and transplanted to other environments. Amniox utilizes its proprietary CRYOTEK process, a cryopreservation technology, to preserve the biological and structural integrity of these tissues.
This study was conducted to evaluate how the different processing methods, cryopreservation and dehydration, affect the structural integrity and biological composition of key signaling molecules within umbilical cord and amniotic membrane tissues. “The successful commercialization of any tissue product relies on the effective preservation of its key biological components, which are essential to maintaining the intended action of the tissue,” said Aaron C. Smith, General Manager of Amniox. “This study intended to verify whether different processing methods might affect tissue integrity and therapeutic potential.”
The results indicated that cryopreservation better preserves the structural integrity and biological signaling molecules of these tissues. “Our findings support the notion that cryopreservation did not cause notable changes in the original relevant tissue characteristics of the umbilical cord/amniotic membrane matrix when compared to fresh tissue, while dehydration drastically altered the structural and biological integrity of the tissue,” said Scheffer C.G. Tseng, MD, PhD, Chief Science Officer of TissueTech. “It definitively brings to light the considerable differences in the structural and biological properties of cryopreserved and dehydrated placental tissues.”
Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing regenerative therapies processed from amniotic membrane and umbilical cord matrix utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. AMNIOX Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.biotissue.com.
About TissueTech, Inc.
TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, more than 130,000 human implants have been conducted using the Company’s patented CRYOTEK process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in mesenchymal stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.
PURION® is a registered trademark of MiMedX Group, Inc.
For Amniox Medical, Inc.
Amy Phillips, 412-327-9499